New cell therapy targets Hard-to-Treat lymphoma
NCT ID NCT07476066
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new treatment called SYS6055 for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses specially designed cells to target and attack cancer cells. The trial will check if it is safe, what dose works best, and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYS6055 (a type of cell therapy targeting CD19 on cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with aggressive B-cell lymphoma that has not responded to standard therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the treatment may not work or could cause serious side effects. It is not yet proven to be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.